-Locally advanced or metastatic pancreatic adenocarcinoma in patients previously treated with 5-fluorouracil.

-Locally advanced or metastatic non-small cell lung cancer (NSCLC)

– Metastatic Breast Cancer after failure of prior anthracycline-containing adjuvant chemotherapy unless anthracycline is clinical contraindicated.

Treatment of advanced ovarian cancer that has relapsed at least 6 months after completion of platinum-based therapy

Unlabeled Uses:
– Treatment of biliary cancer
– Bladder cancer
– Relapsed or refractory testicular cancer
– Squamous cell carcinoma of the head and neck

SKU: GEMOSANZ-1000 1g VIAL 50ml
MOLECULE: Gemcitabine
THERAPEUTIC CLASS: Antineoplastic

FORMULATION:
Each vial contains:
Gemcitabine Hydrochloride eq. to Gemcitabine…200mg
Mannitol USP…200mg
Sodium acetate…12.5mg

Pancreatic Adenocarcinoma
Patient with locally advanced or metastatic cases: 1,000 mg/m2 once weekly via infusion over 30 minutes for 7 weeks followed by 1 week rest, then once weekly for 3 consecutive week out of every 4 week cycle. Dosage may reduce with each cycle or within a cycle based on toxicity.

Non-small cell lung cancer
Patient with locally advanced or metastatic cases: Monotherapy: 1,000 mg/m2 once weekly via infusion over 30 minutes for 3 weeks followed by 1 week rest for locally advanced or metastatic cases. This 4 weeks cycle is then repeated. Combination therapy with cisplatin: 1,000 mg/m2 via infusion over 30 minutes on days 1, 8, and 15 of a 28-days cycle. Alternatively, gemcitabine 1,250 mg/m2 via infusion over 30 minutes on days 1 and 8 of a 21-days cycle. Dosage may reduce with each cycle or within a cycle based on toxicity.

Ovarian cancer
Adult: Patient with locally advanced or metastatic epithelial cases: Combination therapy with carboplatin: 1,000 mg/m2 via infusion over 30 min on days 1 and 8 of a 21-day cycle. Dosage may reduce with each cycle or within a cycle based on toxicity.

Breast cancer
Adult: Patient with unresectable, locally recurrent, or metastatic cases: Combination therapy with paclitaxel: 1,250 mg/m2 via infusion over 30 minutes on days 1 and 8 of a 21-days cycle. Dosage may reduce w/ each cycle or w/in a cycle based on toxicity. Patients should have absolute granulocyte count of ≥1,500 x 106/L prior to initiation of therapy.